← FDA DRUG APPROVALS

FDA ANDA · ANDA040105

OXYCODONE AND ACETAMINOPHEN

Sponsor: PH HEALTH

APPLICATION
ANDA040105
TYPE
ANDA
ORIGINAL APPROVAL
1996-07-30
LATEST ACTION
2026-06-18
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

OXYCODONE AND ACETAMINOPHENDiscontinued
ACETAMINOPHEN 325MG, OXYCODONE HYDROCHLORIDE 5MG · TABLET · ORAL

Approval history

2026-06-18REMS · Supplement 41AP
2024-10-31REMS · Supplement 39AP
2024-03-12Labeling · Supplement 38 · standardAP
2023-12-18Labeling · Supplement 36 · standardAP
2023-12-18Labeling · Supplement 37 · standardAP
2021-03-04Labeling · Supplement 35 · standardAP
2019-10-08Labeling · Supplement 34 · standardAP
2018-09-21Labeling · Supplement 32 · standardAP
2018-09-18REMS · Supplement 31 · standardAP
2016-12-16Labeling · Supplement 28 · standardAP
2016-12-16Labeling · Supplement 24 · standardAP
2016-12-16Labeling · Supplement 27 · standardAP
2013-10-18Labeling · Supplement 15 · standardAP
2011-07-21Labeling · Supplement 9AP
2007-05-29Labeling · Supplement 5AP
1997-09-17Manufacturing (CMC) · Supplement 2AP
1997-09-17Manufacturing (CMC) · Supplement 1AP
1996-07-30OriginalREMSAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →